Literature DB >> 16221765

Divergent effects of matrix metalloproteinases 3, 7, 9, and 12 on atherosclerotic plaque stability in mouse brachiocephalic arteries.

Jason L Johnson1, Sarah J George, Andrew C Newby, Christopher L Jackson.   

Abstract

Matrix metalloproteinases (MMPs) are thought to be involved in the growth, destabilization, and eventual rupture of atherosclerotic lesions. Using the mouse brachiocephalic artery model of plaque instability, we compared apolipoprotein E (apoE)/MMP-3, apoE/MMP-7, apoE/MMP-9, and apoE/MMP-12 double knockouts with their age-, strain-, and sex-matched apoE single knockout controls. Brachiocephalic artery plaques were significantly larger in apoE/MMP-3 and apoE/MMP-9 double knockouts than in controls. The number of buried fibrous layers was also significantly higher in the double knockouts, and both knockouts exhibited cellular compositional changes indicative of an unstable plaque phenotype. Conversely, lesion size and buried fibrous layers were reduced in apoE/MMP-12 double knockouts compared with controls, and double knockouts had increased smooth muscle cell and reduced macrophage content in the plaque, indicative of a stable plaque phenotype. ApoE/MMP-7 double knockout plaques contained significantly more smooth muscle cells than controls, but neither lesion size nor features of stability were altered in these animals. Hence, MMP-3 and MMP-9 appear normally to play protective roles, limiting plaque growth and promoting a stable plaque phenotype. MMP-12 supports lesion expansion and destabilization. MMP-7 has no effect on plaque growth or stability, although it is associated with reduced smooth muscle cell content in plaques. These data demonstrate that MMPs are directly involved in atherosclerotic plaque destabilization and clearly show that members of the MMP family have widely differing effects on atherogenesis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16221765      PMCID: PMC1266110          DOI: 10.1073/pnas.0506201102

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  42 in total

1.  Healed plaque ruptures and sudden coronary death: evidence that subclinical rupture has a role in plaque progression.

Authors:  A P Burke; F D Kolodgie; A Farb; D K Weber; G T Malcom; J Smialek; R Virmani
Journal:  Circulation       Date:  2001-02-20       Impact factor: 29.690

2.  Localization of stromelysin gene expression in atherosclerotic plaques by in situ hybridization.

Authors:  A M Henney; P R Wakeley; M J Davies; K Foster; R Hembry; G Murphy; S Humphries
Journal:  Proc Natl Acad Sci U S A       Date:  1991-09-15       Impact factor: 11.205

Review 3.  Stability and instability: two faces of coronary atherosclerosis. The Paul Dudley White Lecture 1995.

Authors:  M J Davies
Journal:  Circulation       Date:  1996-10-15       Impact factor: 29.690

4.  Differential regulation of platelet aggregation by matrix metalloproteinases-9 and -2.

Authors:  C Fernandez-Patron; M A Martinez-Cuesta; E Salas; G Sawicki; M Wozniak; M W Radomski; S T Davidge
Journal:  Thromb Haemost       Date:  1999-12       Impact factor: 5.249

5.  Plaque rupture after short periods of fat feeding in the apolipoprotein E-knockout mouse: model characterization and effects of pravastatin treatment.

Authors:  Jason Johnson; Kevin Carson; Helen Williams; Sharada Karanam; Andrew Newby; Gianni Angelini; Sarah George; Christopher Jackson
Journal:  Circulation       Date:  2005-03-22       Impact factor: 29.690

6.  The metalloproteinase matrilysin proteolytically generates active soluble Fas ligand and potentiates epithelial cell apoptosis.

Authors:  W C Powell; B Fingleton; C L Wilson; M Boothby; L M Matrisian
Journal:  Curr Biol       Date:  1999 Dec 16-30       Impact factor: 10.834

7.  Progression of coronary atherosclerosis is associated with a common genetic variant of the human stromelysin-1 promoter which results in reduced gene expression.

Authors:  S Ye; P Eriksson; A Hamsten; M Kurkinen; S E Humphries; A M Henney
Journal:  J Biol Chem       Date:  1996-05-31       Impact factor: 5.157

8.  Plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome.

Authors:  Y Inokubo; H Hanada; H Ishizaka; T Fukushi; T Kamada; K Okumura
Journal:  Am Heart J       Date:  2001-02       Impact factor: 4.749

9.  Matrilysin is expressed by lipid-laden macrophages at sites of potential rupture in atherosclerotic lesions and localizes to areas of versican deposition, a proteoglycan substrate for the enzyme.

Authors:  I Halpert; U I Sires; J D Roby; S Potter-Perigo; T N Wight; S D Shapiro; H G Welgus; S A Wickline; W C Parks
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-03       Impact factor: 11.205

10.  Metalloelastase is required for macrophage-mediated proteolysis and matrix invasion in mice.

Authors:  J M Shipley; R L Wesselschmidt; D K Kobayashi; T J Ley; S D Shapiro
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-30       Impact factor: 11.205

View more
  126 in total

Review 1.  The role of matrix metalloproteinases in atherothrombosis.

Authors:  Daniel F J Ketelhuth; Magnus Bäck
Journal:  Curr Atheroscler Rep       Date:  2011-04       Impact factor: 5.113

2.  Apparent tradeoff of higher activity in MMP-12 for enhanced stability and flexibility in MMP-3.

Authors:  Xiangyang Liang; A Arunima; Yingchu Zhao; Rajagopalan Bhaskaran; Anuradha Shende; Todd S Byrne; Jeremy Fleeks; Mark O Palmier; Steven R Van Doren
Journal:  Biophys J       Date:  2010-07-07       Impact factor: 4.033

Review 3.  Matrix metalloproteinases, a disintegrin and metalloproteinases, and a disintegrin and metalloproteinases with thrombospondin motifs in non-neoplastic diseases.

Authors:  Takayuki Shiomi; Vincent Lemaître; Jeanine D'Armiento; Yasunori Okada
Journal:  Pathol Int       Date:  2010-07       Impact factor: 2.534

4.  Deletion of tenascin-C gene exacerbates atherosclerosis and induces intraplaque hemorrhage in Apo-E-deficient mice.

Authors:  Lai Wang; Wei Wang; Prediman K Shah; Lei Song; Mingjie Yang; Behrooz G Sharifi
Journal:  Cardiovasc Pathol       Date:  2012-02-01       Impact factor: 2.185

Review 5.  Matrix metalloproteinase inhibitors as investigative tools in the pathogenesis and management of vascular disease.

Authors:  Mina M Benjamin; Raouf A Khalil
Journal:  Exp Suppl       Date:  2012

Review 6.  Matrix Metalloproteinases, Vascular Remodeling, and Vascular Disease.

Authors:  Xi Wang; Raouf A Khalil
Journal:  Adv Pharmacol       Date:  2017-09-19

Review 7.  Auto-antibodies as emergent prognostic markers and possible mediators of ischemic cardiovascular diseases.

Authors:  P Roux-Lombard; S Pagano; F Montecucco; N Satta; N Vuilleumier
Journal:  Clin Rev Allergy Immunol       Date:  2013-02       Impact factor: 8.667

Review 8.  Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease.

Authors:  Joseph D Raffetto; Raouf A Khalil
Journal:  Biochem Pharmacol       Date:  2007-07-07       Impact factor: 5.858

9.  Solution structure of inhibitor-free human metalloelastase (MMP-12) indicates an internal conformational adjustment.

Authors:  Rajagopalan Bhaskaran; Mark O Palmier; Nusayba A Bagegni; Xiangyang Liang; Steven R Van Doren
Journal:  J Mol Biol       Date:  2007-10-16       Impact factor: 5.469

10.  Effect of matrix metalloproteinase-9 knockout on vein graft remodelling in mice.

Authors:  Anita C Thomas; Andrew C Newby
Journal:  J Vasc Res       Date:  2009-12-16       Impact factor: 1.934

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.